A bibliometric analysis of the research status and trends in studies on polymyositis and dermatomyositis with interstitial lung disease from 2000 to 2022 using Web of Science

被引:0
|
作者
Ma, Xiao-Na [1 ,2 ]
Feng, Wei [1 ,2 ]
Chen, Shu-Lin [1 ,2 ]
Zhong, Xiao-Qin [1 ,2 ]
Zheng, Xue-Xia [1 ,2 ]
Lin, Chang-Song [1 ,2 ,3 ]
Xu, Qiang [1 ,2 ,3 ]
机构
[1] Guangzhou Univ Chinese Med, Clin Med Coll 1, State Key Lab Tradit Chinese Med Syndrome, Guangzhou, Guangdong, Peoples R China
[2] Guangzhou Univ Tradit Chinese Med, Affiliated Hosp 1, Dept Rheumatol, Guangzhou, Guangdong, Peoples R China
[3] Guangzhou Univ Tradit Chinese Med, Affiliated Hosp 1, Dept Rheumatol, Guangzhou 510405, Guangdong, Peoples R China
关键词
bibliometric analysis; hotspots; interstitial lung disease; polymyositis/dermatomyositis; research trend; AUTOANTIBODIES; CADM-140; MYOSITIS; ADULT;
D O I
10.1002/iid3.1190
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
BackgroundThe main subtypes of idiopathic inflammatory myopathies (IIMs)-polymyositis (PM) and dermatomyositis (DM)-are often presented as interstitial lung disease (ILD) in clinical practice; therefore, many researchers have combined the three studies into PM/DM with ILD.MethodsUsing bibliometrics, the research status, progress, and hotspots of PM/DM with ILD between 2000 and 2022 were studied. Literature data on PM/DM with ILD were retrieved from the Web of Science (WoS) database for the research period. Visualization software, including VOSviewer, Pajek, CiteSpace, and Scimago Graphica were used for bibliometric analysis.ResultsA total of 1555 relevant articles were obtained, and the overall research in this field showed an increasing trend. Regarding contributing countries and venues, Japan published the most articles while Rheumatology was the most prolific journal. Regarding authors, the most published article was by Wang Guochun from Changchun University of Technology in China. Keyword analysis and cocited literature cluster analysis showed that diagnosis, classification, autoantibodies, antibodies, prognosis, complications, and treatment of PM/DM with ILD have been hot topics in this field recently. Moreover, our study shows that anti-mda5 antibody, mortality, gene 5 antibody, IIMs, double-blind, and prognostic factors, among others, may be new hot topics.ConclusionThis study found that research on PM/DM with ILD has increased over time, and scholars are paying more attention to this field. The development of new drugs for the management, treatment, and prevention of PM/DM with ILD is the primary task of researchers and a direction for future research in this field. Based on the Web of Science database, the current status and trends of research on polymyositis (PM)/dermatomyositis (DM) with interstitial lung disease (ILD) (2000-2022) were analyzed in terms of annual publications, authors, institutions, countries, and keywords. The study found that researchers' interest in PM/DM with ILD has been increasing year by year, and the diagnosis, classification, autoantibodies, antibodies, prognosis, complications, and treatment of PM/DM with ILD have been a hot topic in the field. Anti-mda5 antibody, mortality, gene 5 antibody, idiopathic inflammatory myopathies, double-blind, and prognostic factors, among others, may be new hot topics. image
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Prevalence of interstitial lung disease in polymyositis and dermatomyositis: A meta-analysis from 2000 to 2020
    Sun, Kun-Yan
    Fan, Yong
    Wang, Yun-Xia
    Zhong, Yi-Jue
    Wang, Guang-Fa
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2021, 51 (01) : 175 - 191
  • [2] Clinical analysis and outcome of interstitial lung disease complicated with juvenile dermatomyositis and juvenile polymyositis
    Sato, Satoshi
    Uejima, Yoji
    Nanbu, Meika
    Suganuma, Eisuke
    Takano, Tadamasa
    Tanaka, Risa
    Kabuki, Tomoyuki
    Oguma, Eiji
    Oh-Ishi, Tsutomu
    Kawano, Yutaka
    MODERN RHEUMATOLOGY, 2017, 27 (04) : 652 - 656
  • [3] Exploration of pathomechanism using comprehensive analysis of serum cytokines in polymyositis/dermatomyositis-interstitial lung disease
    Matsuda, Shogo
    Kotani, Takuya
    Ishida, Takaaki
    Fukui, Keisuke
    Fujiki, Youhei
    Suzuka, Takayasu
    Nagai, Koji
    Hata, Kenichiro
    Shoda, Takeshi
    Isoda, Kentaro
    Ito, Yuri
    Makino, Shigeki
    Takeuchi, Tohru
    Arawaka, Shigeki
    RHEUMATOLOGY, 2020, 59 (02) : 310 - 318
  • [4] Research Hotspots and Thematic Trends in the Management of Preeclampsia: A Bibliometric Analysis from 2000 to 2022
    Shen, Xiao
    Tao, Yuchen
    Wang, Yixiao
    Obore, Nathan
    Yu, Hong
    REPRODUCTIVE SCIENCES, 2024, : 815 - 824
  • [5] Research trends in vulnerability studies from 2000 to 2019: Findings from a bibliometric analysis
    Kim, Byeong Je
    Jeong, Seunghoo
    Chung, Ji-Bum
    INTERNATIONAL JOURNAL OF DISASTER RISK REDUCTION, 2021, 56
  • [6] Research trends and hotspots for frontotemporal dementia from 2000 to 2022: a bibliometric analysis
    Chen, Xinxin
    Chen, Yin
    Ni, Biyu
    Huang, Cheng
    FRONTIERS IN NEUROLOGY, 2024, 15
  • [7] Status and trends of personalized medicine research from 2000 to 2020: a bibliometric analysis
    Konar, Naime Meric
    Karaismailoglu, Serkan
    Karaismailoglu, Eda
    CURRENT MEDICAL RESEARCH AND OPINION, 2022, 38 (05) : 837 - 846
  • [8] Global research trends of infantile hemangioma: A bibliometric and visualization analysis from 2000 to 2022
    Lin, Qian
    Cai, Beichen
    Shan, Xiuying
    Ni, Xuejun
    Chen, Xuanfeng
    Ke, Ruonan
    Wang, Biao
    HELIYON, 2023, 9 (11)
  • [9] Global research trends in tongue cancer from 2000 to 2022: bibliometric and visualized analysis
    Wu, Beibei
    Zhang, Tong
    Dai, Ning
    Luo, Ding
    Wang, Xuejie
    Qiao, Chen
    Liu, Jian
    CLINICAL ORAL INVESTIGATIONS, 2024, 28 (02)
  • [10] Global research trends and hot spots on autophagy and kidney diseases: a bibliometric analysis from 2000 to 2022
    Ai, Sinan
    Li, Yake
    Zheng, Huijuan
    Wang, Zhen
    Liu, Weijing
    Tao, Jiayin
    Li, Yaotan
    Wang, Yaoxian
    FRONTIERS IN PHARMACOLOGY, 2023, 14